MFT-6112 v4

Wegmann, J. (2021). Psychopharmacology: Straight talk on mental health medications (4th ed.). PESI.
Read Chapter 13
Provides an overview of anti-anxiety and sleep medications.

Preston, J. D., O'Neal, J. H., Talaga, M. C., & Moore, B. A. (2021). Handbook of clinical psychopharmacology for therapists. New Harbinger Publications.
Review Chapter 4
Discusses how pharmacology can be used as part of a multidisciplinary approach to treatment.

Slack, Inc. (2023). FDA-approved drugs for treatment of sleep disorders and excessive daytime sleepiness. Journal of Psychosocial Nursing and Mental Health Services, 61(10), 5.
Identified pharmacological interventions aimed at treating sleep disorders.

Heidenreich, S., Ross, M., Chua, G. N., Seboek Kinter, D., & Phillips-Beyer, A. (2022). Preferences of patients for benefits and risks of insomnia medications using data elicited during two phase III clinical trials. Sleep: Journal of Sleep and Sleep Disorders Research, 45(11), 1–12.
Mentions the benefits and risks of medications to treat sleep disorders.

Del Casale, A., Bonanni, L., Bargagna, P., Novelli, F., Fiaschè, F., Paolini, M., Forcina, F., Anibaldi, G., Cortese, F. N., Iannuccelli, A., Adriani, B., Brugnoli, R., Girardi, P., Paris, J., & Pompili, M. (2021). Current clinical psychopharmacology in borderline personality disorder. Current Neuropharmacology, 19(10), 1760–1779.
Discusses current treatment trends for borderline personality disorder.

Pascual, J. C., Arias, L., & Soler, J. (2023). Pharmacological management of borderline personality disorder and common comorbidities. CNS Drugs, 37(6), 489–497.
Describes how to treat borderline personality disorder with psychopharmacological treatments.